Pharmacokinetic Research in Pediatric HIV/TB Co-Infection (R21)

The summary for the Pharmacokinetic Research in Pediatric HIV/TB Co-Infection (R21) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Pharmacokinetic Research in Pediatric HIV/TB Co-Infection (R21)
	CFDA Number:	93.242
	CFDA Description:	Mental Health Research Grants
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health Income Security and Social Services
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-HD-09-016
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Mar 03, 2010
	Creation Date:	Mar 04, 2010
	Original Closing Date for Applications:	Aug 24, 2010
	Current Closing Date for Applications:	Aug 24, 2010
	Archive Date:	Sep 24, 2010
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: Purpose. This Funding Opportunity Announcement (FOA), issued by the National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), encourages Exploratory/Developmental Research Grant Award (R21) applications from institutions/organizations that propose to evaluate the pharmacokinetics of anti-tuberculosis (anti-TB) drugs and pharmacokinetic drug interactions between anti-TB drugs and anti-HIV medications in children with HIV/TB co-infection. Research in this area lags far behind that in adults due to the many challenges surrounding the diagnosis and management of TB disease in children. Research related to the treatment of TB in the context of pediatric HIV/TB co-infection is urgently needed. This FOA will support investigator-initiated grants to define appropriate dosing of anti-TB agents in HIV-infected children and will generate knowledge leading to the optimization of management of TB/HIV co-infection in children, including the management of central nervous system (CNS) involvement with TB through the evaluation of CNS penetration of anti-TB agents in the context of antiretroviral therapy. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental Research Grant (R21) award mechanism and is issued in parallel with an FOA of identical scientific scope, RFA-HD-09-015 that encourages applications under the R01 grant mechanism. Funds Available and Anticipated Number of Awards. The NICHD intends to commit $250,000 (total costs), and NIMH intends to commit $150,000 (total costs) in FY 2010 to support one to two meritorious applications. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-hd-09-016.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R21); • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R03); • Advancing the Impact of Effective HIV/AIDS Prevention and Treatment Interventions (R03); • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R34); • Advancing the Impact of Effective HIV/AIDS Prevention and Treatment Interventions (R34); • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R42]); • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44]); • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44]); • Pharmacologic Agents and Drugs for Mental Disorders (STTR [R41/R42]); • Solicitation of Assays for High Throughput Screening (HTS) in the Molecular Libraries Screening Cent...